Loading...
ENDP.Q logo

Endo, Inc.OTCPK:ENDP.Q Aktierapport

Marknadsvärde US$141.1k
Aktiekurs
n/a
US$16.66
ej tillgängligintrinsisk rabatt
1Y-98.9%
7D0%
1D
Portföljens värde
​
Utsikt

Endo, Inc.

OTCPK:ENDP.Q Aktierapport

Börsvärde: US$141.1k

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Endo International (ENDP.Q) Aktievy

A specialty pharmaceutical company, develops, manufactures, markets, and sells various pharmaceutical products in the United States and internationally. Mer information

ENDP.Q fundamental analys
Snöflinga Score
Värdering4/6
Framtida tillväxt0/6
Tidigare resultat0/6
Finansiell hälsa2/6
Utdelningar0/6

Belöningar

Handlar till 100% under vår uppskattning av dess verkliga värde

Riskanalys

Mycket volatil aktiekurs under de senaste 3 månaderna jämfört med US marknaden

Negativt eget kapital

Intäkterna har minskat med 41.7% per år under de senaste 5 åren

Har inte ett meningsfullt börsvärde ( $141K )


ENDP.Q Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Endo International plc Konkurrenter

Prishistorik och prestanda

Sammanfattning av aktiekursernas upp- och nedgångar samt förändringar för Endo International
Historiska aktiekurser
Aktuell aktiekursUS$0.0006
52 veckors högstaUS$0.08
52 veckors lägstaUS$0.000001
Beta0.80
1 månads förändring50.00%
3 månaders förändring0%
1 års förändring-98.91%
3 års förändring-99.99%
5 års förändring-99.99%
Förändring sedan börsintroduktionen-100.00%

Senaste nyheter och uppdateringar

Recent updates

Seeking Alpha • Aug 16

Endo creditors looking at putting company up for sale through bankruptcy - Bloomberg

Endo International (NASDAQ:ENDP) creditors are looking at putting the pharma company up for sale through a bankruptcy, likely through a Chapter 11 filing in New York, Bloomberg reported. Endo (ENDP) has a debt load of more than $8B and is still facing many lawsuits over its alleged role in the nation's opioid epidemic. A bankruptcy filing would make it easier for Endo (ENDP) to make deals with with governments and other entities suing the company. Bloomberg said that some first-lien lenders are competing to use their debt holdings toward a bid for the company’s assets. Seeking Alpha contributor CashFlow Hunter, which has a strong sell rating on Endo (ENDP), has said a bankruptcy filing is imminent.
Seeking Alpha • Aug 03

Endo International sees 23% rise on 3x higher than normal volume

Shares of Endo International (NASDAQ:ENDP) have risen sharply and are up 23% Wednesday afternoon amid three times higher than usual daily volume. The drugmaker's average daily volume is ~46.2M shares. As of 215p ET, more than 138M shares had traded hands. Endo (ENDP) is also having unusual options trading volume that is six times the daily normal. Seeking Alpha contributor CashFlow Hunter says the company is a strong sell with a bankruptcy filing likely.
Seeking Alpha • Jul 25

Endo outperforms defying bankruptcy fears and generic entry

The shares of Endo International (NASDAQ:ENDP) rose sharply on Monday even as the company continues to grapple with concerns over the generic threat to a key drug, failure to fulfill debt commitments, and potential bankruptcy filing amid ongoing opioid litigation. Despite an ~89% YTD decline, Endo (ENDP) has added ~13% over the past 30 days outperforming the broader market, as shown in this graph. The upsurge comes despite a recent WSJ report on the company’s plan to file for Chapter 11 bankruptcy without striking a settlement on thousands of opioid claims. In June, Dublin, Ireland-based Endo (ENDP) opted to skip interest payments owed to its junior bondholders citing the ongoing talks with certain creditors regarding its decision to evaluate strategic alternatives. A decline in earnings, driven in part by the loss of exclusivity for its leading sales generator, Vasostrict, has exacerbated the operational issues. In May, Piper Sandler downgraded Endo (ENDP), noting the generic competition to the vasopressin injection, which added $155.9M to the company topline in 1Q 2022 with ~30% YoY decline.
Seeking Alpha • Jul 12

Endo weighs bankruptcy filing without opioid settlement - WSJ

Endo International (NASDAQ:ENDP) shares plunged ~20% Tuesday after The Wall Street Journal reported that the generic drugmaker is advancing towards a bankruptcy filing without reaching a settlement on opioid claims against the company. According to people familiar with the matter, despite years of negotiations with opioid claimants, Endo (ENDP) is weighing chapter 11 bankruptcy to restructure its over $8B debt and thousands of ongoing litigations. Endo (ENDP) has been negotiating with a group of senior creditors after the company missed interest payments to junior bondholders last month, the people said, adding that the management expects to reach a deal with them before a near-term bankruptcy process starts. However, a bankruptcy filing is unlikely if the company inks agreements with junior bondholders and opioid plaintiffs, the people said, noting that the situation could change. Endo (ENDP) declined to comment. Read: “Bankruptcy filing should be imminent” for Endo (ENDP), Seeking Alpha contributor CashFlow Hunter predicted in May.
Seeking Alpha • Jun 29

Endo International cools off, giving back some of its 85% Tuesday gain

Shares of Endo International are down 24% in Wednesday afternoon trading, a day after the pharma closed up 85%. The reason for Tuesday's surge was a news release issued by law firm White & Case on behalf of a group of institutional investors holding unsecured notes in Endo (NASDAQ:ENDP) subsidiaries. The group has proposed that the company commence a cash tender offer or commence a debt-for-debt exchange. Also, it is against a near-term bankruptcy filing as Endo (ENDP) has strong liquidity and it "could destroy significant value for stakeholders." Endo (ENDP) has been struggling as a result of multi-million-dollar settlements in state opioid crisis cases.
Seeking Alpha • May 10

Endo: Stick A Fork In It

Second quarter guidance implies catastrophic sales and margins from Vasostrict. Bonds plummeted implying first lien debt might be impaired. Possibly impairment of first lien debt and near certain impairment of second lien debt means zero equity value. Bankruptcy filing should be imminent.
Seeking Alpha • Mar 07

Endo: About As Bad As It Gets

Entrance of generic competitor to Vasostrict materially hurting revenue. QWO uptake seems slow with concerns around discoloration side-effect. Q1 guide implies leverage rising dangerous levels. Bankruptcy seems like an increasingly likely option.
Seeking Alpha • Dec 16

Endo: FDA Approves Generic Form Of Vasostrict Creating Headwind Into Next Year

Eagle Pharmaceuticals receives FDA approval to sell a generic form of vasopressin, a competitor to ENDP's Vasostrict. This approval follows Eagle's courtroom win in a patent dispute with Endo several months ago. Vasostrict is Endo's biggest revenue source, responsible for $786 million of high margin sales last year. Eagle expects 180-day marketing exclusivity for vasopressin. Continue to see the stock as high risk.
Seeking Alpha • Nov 02

Endo: A Win In California But Equity Value Still A Question

California State Court hands Endo and other opioid producers a temporary win in liability trial. Tentative ruling directs manufacturers to file a statement of decision within 30 days. Ruling likely takes away major liability in the country's biggest state at least for a while. Leverage remains too high, particularly with Vasostrict EBITDA at risk. Bankruptcy is now likely off the table but struggle to see equity value.
Seeking Alpha • Aug 31

Endo International: Loses Vasostrict Trial

Judge rules Eagle Pharmaceuticals' version of the drug does not infringe on two patents held by Par Pharmaceuticals, the unit that produces vasostrict. Expect Eagle to start producing and marketing a generic form of vasostrict to treat low blood pressure in the next few months. Approximately 30% of Endo Pharmaceuticals' revenue and EBITDA will take a hit. The loss likely wipes out any equity value for Endo and impairs unsecured bonds.
Seeking Alpha • Aug 20

Endo International: Hires Restructuring Advisor

The company is hiring Alvarez & Marsal, which specializes in bankruptcy restructuring. The move is somewhat surprising from a timing perspective. New York opioid and Vasostrict trials are still ongoing.
Seeking Alpha • Aug 07

Endo International: All About Ongoing Litigation

Company settled with the eastern TN counties for $35mm but do the economics make any sense? NY litigation is ongoing with plaintiffs seeking default liability judgment on the same grounds as TN. Vasostrict trial with Eagle Pharmaceuticals is ongoing. >25% of EBITDA at risk. Quarter operationally solid, but questions remain on market acceptance of QWO.
Seeking Alpha • Jul 15

Endo: Appellate Court Denies Request To Postpone Damages Trial Might Be End O' The Road

The denied request is likely the last chance to stop the Tennessee damages trial set to begin on July 26. The company already has a default judgment against it. The company could face a $2.4 billion judgment leveled against it. Appeal denial is one more piece pointing to likely bankruptcy filing.
Seeking Alpha • Jun 30

Endo International: Bankruptcy Seems Like The Only Practical Option

A Tennessee state court issued a "default judgement" in April against the company in the lawsuit by county prosecutors over the company's generic for oxycontin, Opana. Earlier this month, a Tennessee appellate court declined to review that default judgement. The damages trial begins on July 26 in Tennessee. Plaintiffs are seeking $2.4 billion. A trial for a suit against the company begins in New York on June 28th and a California trial is ongoing. A bankruptcy filing is very likely the only way to settle all of these cases in a manner that preserves value.

Aktieägarnas avkastning

ENDP.QUS PharmaceuticalsUS Marknad
7D0%2.7%-2.4%
1Y-98.9%38.2%21.5%

Avkastning vs industri: ENDP.Q presterade sämre än US Pharmaceuticals branschen som gav 38.2 % under det senaste året.

Avkastning vs Marknaden: ENDP.Q presterade sämre än US marknaden som gav 21.5 % under det senaste året.

Prisvolatilitet

Is ENDP.Q's price volatile compared to industry and market?
ENDP.Q volatility
ENDP.Q Average Weekly Movement207.3%
Pharmaceuticals Industry Average Movement10.0%
Market Average Movement7.3%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.1%

Stabil aktiekurs: ENDP.Q s aktiekurs har varit volatil under de senaste 3 månaderna jämfört med marknaden för US.

Volatilitet över tid: ENDP.Q s veckovolatilitet har ökat från 125% till 207% under det senaste året.

Om företaget

GrundadAnställdaVD OCH KONCERNCHEFWebbplats
19972,931Blaise Colemanwww.endo.com

Endo International plc Sammanfattning av grunderna

Hur förhåller sig Endo International:s resultat och omsättning till dess börsvärde?
ENDP.Q grundläggande statistik
BörsvärdeUS$141.13k
Vinst(TTM)-US$2.45b
Intäkter(TTM)US$2.01b
0.0x
P/S-förhållande
0.0x
P/E-förhållande

Är ENDP.Q övervärderat?

Se Verkligt värde och värderingsanalys

Resultat & intäkter

Viktig lönsamhetsstatistik från den senaste resultatrapporten (TTM)
ENDP.Q resultaträkning (TTM)
IntäkterUS$2.01b
Kostnad för intäkterUS$941.90m
BruttovinstUS$1.07b
Övriga kostnaderUS$3.52b
Intäkter-US$2.45b

Senast redovisade vinst

Dec 31, 2023

Nästa vinstdatum

n/a

Vinst per aktie (EPS)-10.41
Bruttomarginal53.17%
Nettovinstmarginal-121.69%
Skuld/egenkapitalförhållande-123.5%

Hur har ENDP.Q utvecklats på lång sikt?

Se historisk utveckling och jämförelse

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2024/05/02 11:04
Aktiekurs vid dagens slut2024/05/02 00:00
Intäkter2023/12/31
Årlig intjäning2023/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Endo, Inc. bevakas av 32 analytiker. 0 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Richard SilverBarclays
Gary NachmanBMO Capital Markets Equity Research
Sumant Satchidanand KulkarniBofA Global Research